NeuroRx Secures Notice of Patent Allowance for PTSD Formulation

November 5, 2020

The U.S. Patent and Trademark Office has granted NeuroRx a patent for a post-traumatic stress disorder (PTSD) treatment.

The patent covers the combination of ketamine with the company's formulation of an antibiotic called D-cycloserine and an anti-depressant agent, the Radnor, Pa., drugmaker said. Ketamine is a short-acting anesthetic also used for the treatment of pain and depression.

According to the National Institutes of Health, PTSD affects 10 million to 13 million people in the U.S.

View today's stories